Drug Trial Radar · NCT06941844
A Phase 3 Trial of DT120 for Major Depressive Disorder (Emerge)
Last checked: Nov 19, 2026Latest source record: Aug 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
149
Actual
Start
Apr 14, 2025
Primary completion
May 20, 2026
Study completion Feb 2027
Sponsor
- Lead sponsor
- Definium Therapeutics US, Inc.Industry
- Sponsor type
- Industry
- First posted
- Apr 24, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Emerge
Conditions
- Major Depressive Disorder
Interventions
PlaceboOther
A substance that is designed to have no therapeutic value
DT120Drug
A psychoactive substance that mediates effects mainly through an agonist activity in the serotonin 2A receptor (5-HT2A)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from Baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) total score at Week 6Time frame: Baseline to Week 6
Locations
22 sites in 1 country. Site status is shown where the registry gives one.
Preferred Research Partners, Inc
Little Rock, Arkansas
Kadima Neuropsychiatry Institute
La Jolla, California
Psychedelic Science Institute
Santa Monica, California
Mountain View Clinical Research, Inc
Denver, Colorado
CNS, LLC (Jacksonville)
Jacksonville, Florida
CNS, LLC (Orlando)
Orlando, Florida
Charter Research
Orlando, Florida
Uptown Research Institute (URI), LLC
Chicago, Illinois
Sheppard Pratt
Baltimore, Maryland
Adams Clinical Boston
Boston, Massachusetts
Adams Clinical
Watertown, Massachusetts
University of Missouri
Columbia, Missouri
Cenexel HRI
Berlin, New Jersey
Adams Clinical Harlem
New York, New York
Columbia - New York State Psychiatric Institute
New York, New York
Neuro-Behavioral Clinical Research
Canton, Ohio
University of Cincinnati
Cincinnati, Ohio
Adams Clinical Philadelphia
Philadelphia, Pennsylvania
CNS, LLC (Memphis)
Memphis, Tennessee
Austin Clinical Trial Partners
Austin, Texas
Cedar Clinical Research
Murray, Utah
Memory Clinic, Inc
Bennington, Vermont
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.